AMRX - Amneal Pharmaceuticals, Inc.
| Previous Close | 3.4000 |
| Open | 3.6000 |
| Bid | 3.4500 x 2200 |
| Ask | 3.8000 x 4000 |
| Day's Range | 3.4000 - 3.6600 |
| 52 Week Range | 3.1800 - 24.4800 |
| Volume | 2,370,339 |
| Avg. Volume | 1,573,757 |
| Market Cap | 1.028B |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9450 |
| Earnings Date | Aug 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.05 |
- Yahoo Finance Video•21 days ago
Drugmakers raised prices of over 40 prescription drugs
Yahoo Finance’s Adam Shapiro, Sibile Marcellus, and Rick Newman join Direxion Managing Director Sylvia Jablonski to discuss.
- Investor's Business Daily•9 hours ago
These Pharmas Could Be On The Hook For Billions In The Opioid Epidemic
Generic drug companies Teva Pharmaceutical, Mylan, Endo and Amneal Pharmaceuticals may have to pay $8.5 billion in litigation costs surrounding the opioid epidemic, one analyst says.
- Business Wire•19 hours ago
Amneal Announces Launch of Generic Lyrica®
Amneal Pharmaceuticals, Inc. (AMRX), today announced that it has received approval for, and launched, its generic version of Lyrica® (pregabalin capsules) 25 mg, 50 mg, 75, mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg. The Company has now launched 21 generic products in 2019. “This new generic launch provides an important treatment option for patients and, as our twenty-first generic product launch this year, demonstrates the continued momentum of our generic pipeline,” said Rob Stewart, President and CEO of Amneal.
- GlobeNewswire•5 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Amneal Pharmaceuticals, Inc. - AMRX
Pomerantz LLP is investigating claims on behalf of investors of Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (AMRX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext.
- GlobeNewswire•8 days ago
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Amneal Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Amneal Pharmaceuticals, Inc. (“Amneal” or “the Company”) (NYSE: AMRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- Benzinga•8 days ago
Morgan Stanley Downgrades Teva, Endo On Drug Pricing And Litigation Concerns
Pharmaceutical stocks have been under pressure for the past few trading days, but one Wall Street analyst said the worst is yet to come for a handful of specialty drugmakers. The Analyst Morgan Stanley ...
- Business Wire•10 days ago
AMNEAL INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Amneal Pharmaceuticals, Inc. - AMRX
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Amneal Pharmaceuticals, Inc. (AMRX). For many years, the Company, (formerly Impax Laboratories Inc.), which develops, manufactures, and markets bioequivalent, generic, pharmaceutical products, has been embroiled in investigations and litigation by state and federal authorities and relating to claims that it colluded with other competitor companies in a price-fixing scheme resulting in exponential price increases of certain products.
- Zacks•12 days ago
Amneal (AMRX) Down on Guidance Update & Restructuring Plan
Amneal (AMRX) slumps on news of budget cut and reduction in annual guidance.
- Business Wire•12 days ago
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Amneal Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Amneal Pharmaceuticals, Inc. (“Amneal” or “the Company”) (NYSE: AMRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- ACCESSWIRE•12 days ago
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (AMRX)
NEW YORK, NY / ACCESSWIRE / July 11, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amneal Pharmaceuticals, Inc. (“Amneal ” or the “Company”) (NYSE: ...
- Business Wire•12 days ago
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Amneal Pharmaceuticals, Inc. – AMRX
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Amneal Pharmaceuticals, Inc. resulting from allegations that Amneal may have issued materially misleading business information to the investing public.
- Benzinga•12 days ago
The Daily Biotech Pulse: Neurocrine's Parkinson's Drug Accepted For Review, Sunesis Offering, No Headaches For Biohaven's Migraine Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 10) CONMED Corporation (NASDAQ: CNMD ) Eidos Therapeutics ...
- Business Wire•12 days ago
INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Amneal Pharmaceuticals, Inc. and Encourages Investors With Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Amneal Pharmaceuticals, Inc. (“Amneal” or “the Company”) (NYSE: AMRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- Motley Fool•13 days ago
Why Micro Focus International, MSC Industrial Direct, and Amneal Pharmaceuticals Slumped Today
Company-specific bad news kept these stocks out of the rally.
- Motley Fool•13 days ago
Here's Why Amneal Pharmaceuticals Fell as Much as 36.6% Today
Stubborn headwinds in the generic-drug markets are forcing the company to restructure operations.
- Benzinga•13 days ago
Amneal Announces Restructuring Plan, Cuts Guidance
Amneal Pharmaceuticals (NYSE: AMRX) has reduced EBITDA for 2019 to now be in the range of $425 million to $475 million. Amneal said it factored in continuing market pressure and additional competition on its key generic products, the uncertainty of supply of epinephrine auto-injector (generic Adrenaclick) from its third-party supplier during the high seasonal third quarter, as well as delays in key product approvals and launches including generic NuvaRing. “Recently we initiated an in depth, company-wide review of our organizational structures, operational budgets, current and future capital projects, and existing capability and infrastructure alignments,” said CEO Rob Stewart.
- Reuters•13 days ago
UPDATE 1-Amneal Pharma cuts core profit forecast on allergy shot supply issues
Amneal Pharmaceuticals Inc on Wednesday cut its 2019 core earnings forecast, citing the uncertain supply of epinephrine auto-injectors amid a global shortage of the emergency allergy shots, including Mylan NV's EpiPen. Amneal now expects full-year adjusted earnings before interest, tax, depreciation and amortization in the range $425 million to $475 million, compared with its previous forecast of $600 million to $650 million. The supply disruption has plagued Amneal for over a year, and the company saw its 2018 combined generics net revenue fall 2.6%, hurt mainly by lower sales of its epinephrine auto-injector.
- Business Wire•13 days ago
Amneal Pharmaceuticals Announces Restructuring and Costs Savings Plan to Improve Operations and Position the Company for Future Growth
Amneal Pharmaceuticals, Inc. (AMRX) today announced a comprehensive restructuring plan designed to reduce its cost base, further right size its organization and optimize its global manufacturing infrastructure. “Recently we initiated an in depth, company-wide review of our organizational structures, operational budgets, current and future capital projects, and existing capability and infrastructure alignments,” said Rob Stewart, President and Chief Executive Officer of Amneal. “We undertook this review in response to the continuing industry challenges impacting our business, including ongoing pressure on our base generics business from the limited number of buyers and the greater than expected effect of additional competition on our key generic products.
- Business Wire•14 days ago
Amneal to Report Second Quarter 2019 Results on August 8, 2019
Amneal Pharmaceuticals, Inc. will release its second quarter 2019 financial results on Thursday, August 8, 2019, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m.
- GlobeNewswire•26 days ago
Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Rockwell Medical, Amneal Pharmaceuticals and Intuit and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Rockwell Medical, Inc., Amneal Pharmaceuticals, Inc., and Intuit, Inc. Additional information about each case can be found at the link provided.
- GlobeNewswire•last month
Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Rockwell Medical, Amneal Pharmaceuticals, Kraft Heinz, and Intuit and Encourages Investors to Contact the Firm
NEW YORK, June 18, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Rockwell Medical, Amneal Pharmaceuticals,.
